Rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic and progressive systemic disease of the connective tissue, which is particularly manifested with destructive alterations to the joints. Inflammatory reactions in the synovium lead to the influx of peripheral inflammatory cells as well as the activation of local...

Full description

Saved in:
Bibliographic Details
Published inZeitschrift für Rheumatologie Vol. 77; no. 9; p. 769
Main Authors Neumann, E, Frommer, K, Diller, M, Müller-Ladner, U
Format Journal Article
LanguageGerman
Published Germany 01.11.2018
Subjects
Arthritis, Rheumatoid - immunology
Arthritis, Rheumatoid - therapy
Cytokines
Fibroblasts
Humans
Inflammation
Synovial Membrane
Synovitis
Treatment options
Cytokines
Inflammation
Joint erosion
Online AccessGet full text

Cover

More Information
Summary:Rheumatoid arthritis (RA) is a chronic and progressive systemic disease of the connective tissue, which is particularly manifested with destructive alterations to the joints. Inflammatory reactions in the synovium lead to the influx of peripheral inflammatory cells as well as the activation of local cells. Released growth factors, chemokines and especially cytokines play a key role in chronic inflammatory responses. In addition to the central lymphocytes, the T and B cells and their subpopulations, locally resident cells, such as neutrophils, macrophages and fibroblasts as well as cells of bone metabolism are activated by the inflammatory milieu and contribute to and drive inflammation and tissue damage. The destruction of cartilage and bone substance by local tissue cells, synovial fibroblasts and osteoclasts is characteristic for this disease. Untreated, the local inflammatory and destructive processes as well as systemic inflammatory factors lead to progressive and irreversible joint destruction. Cellular and immunological processes in RA are closely interwoven; therefore, besides the general inhibition of immunological processes, specific inhibition of central key molecules can reduce or completely stop the inflammatory destructive processes; however, a high heterogeneity can be observed among RA patients and disease progression. Therefore, an expansion of the therapeutic options is desirable as not all patients are able to equally benefit from the therapeutic treatment. It is important to characterize new molecular mechanisms, which could lead to the development of new therapeutic options. Some of the more recent insights are summarized in this overview.
ISSN:1435-1250